» Articles » PMID: 38420922

α-Synuclein: Multiple Pathogenic Roles in Trafficking and Proteostasis Pathways in Parkinson's Disease

Overview
Journal Neuroscientist
Publisher Sage Publications
Specialty Neurology
Date 2024 Feb 29
PMID 38420922
Authors
Affiliations
Soon will be listed here.
Abstract

Parkinson's disease (PD) is a common age-related neurodegenerative disorder characterized by the loss of dopaminergic neurons in the midbrain. A hallmark of both familial and sporadic PD is the presence of Lewy body inclusions composed mainly of aggregated α-synuclein (α-syn), a presynaptic protein encoded by the gene. The mechanisms driving the relationship between α-syn accumulation and neurodegeneration are not completely understood, although recent evidence indicates that multiple branches of the proteostasis pathway are simultaneously perturbed when α-syn aberrantly accumulates within neurons. Studies from patient-derived midbrain cultures that develop α-syn pathology through the endogenous expression of PD-causing mutations show that proteostasis disruption occurs at the level of synthesis/folding in the endoplasmic reticulum (ER), downstream ER-Golgi trafficking, and autophagic-lysosomal clearance. Here, we review the fundamentals of protein transport, highlighting the specific steps where α-syn accumulation may intervene and the downstream effects on proteostasis. Current therapeutic efforts are focused on targeting single pathways or proteins, but the multifaceted pathogenic role of α-syn throughout the proteostasis pathway suggests that manipulating several targets simultaneously will provide more effective disease-modifying therapies for PD and other synucleinopathies.

Citing Articles

Synaptic phosphoproteome modifications and cortical circuit dysfunction are linked to the early-stage progression of alpha-synuclein aggregation.

Dutta S, Hensel J, Scott A, Mohallem R, Rossitto L, Khan H bioRxiv. 2025; .

PMID: 39896549 PMC: 11785254. DOI: 10.1101/2025.01.24.634820.


Single-nucleus multi-omics of Parkinson's disease reveals a glutamatergic neuronal subtype susceptible to gene dysregulation via alteration of transcriptional networks.

Shwab E, Gingerich D, Man Z, Gamache J, Garrett M, Crawford G Acta Neuropathol Commun. 2024; 12(1):111.

PMID: 38956662 PMC: 11218415. DOI: 10.1186/s40478-024-01803-1.


Is There a Place for Lewy Bodies before and beyond Alpha-Synuclein Accumulation? Provocative Issues in Need of Solid Explanations.

Lenzi P, Lazzeri G, Ferrucci M, Scotto M, Frati A, Puglisi-Allegra S Int J Mol Sci. 2024; 25(7).

PMID: 38612739 PMC: 11011529. DOI: 10.3390/ijms25073929.

References
1.
Spencer B, Kim C, Gonzalez T, Bisquertt A, Patrick C, Rockenstein E . α-Synuclein interferes with the ESCRT-III complex contributing to the pathogenesis of Lewy body disease. Hum Mol Genet. 2016; 25(6):1100-15. PMC: 4764192. DOI: 10.1093/hmg/ddv633. View

2.
Cuervo A, Stefanis L, Fredenburg R, Lansbury P, Sulzer D . Impaired degradation of mutant alpha-synuclein by chaperone-mediated autophagy. Science. 2004; 305(5688):1292-5. DOI: 10.1126/science.1101738. View

3.
Polymeropoulos M, Lavedan C, Leroy E, Ide S, Dehejia A, Dutra A . Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science. 1997; 276(5321):2045-7. DOI: 10.1126/science.276.5321.2045. View

4.
Fauvet B, Mbefo M, Fares M, Desobry C, Michael S, Ardah M . α-Synuclein in central nervous system and from erythrocytes, mammalian cells, and Escherichia coli exists predominantly as disordered monomer. J Biol Chem. 2012; 287(19):15345-64. PMC: 3346117. DOI: 10.1074/jbc.M111.318949. View

5.
Cookson M . Cellular functions of LRRK2 implicate vesicular trafficking pathways in Parkinson's disease. Biochem Soc Trans. 2016; 44(6):1603-1610. DOI: 10.1042/BST20160228. View